Body mass index and exon 19 mutation as factors predicting the therapeutic efficacy of gefitinib in patients with epidermal growth factor receptor mutation‐positive non‐small cell lung cancer

BACKGROUND: Many randomized clinical trials have demonstrated that epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) are advantageous over standard chemotherapy, either as front‐line treatment or as further management of patients with EGFR mutation‐positive non‐small‐cell lung...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Hongyan, Sun, Xiaoteng, Zhai, Xiaoyu, Guo, Jingfeng, Liu, Yutao, Ying, Jianming, Wang, Ziping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718134/
https://www.ncbi.nlm.nih.gov/pubmed/26816540
http://dx.doi.org/10.1111/1759-7714.12275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718134/
https://www.ncbi.nlm.nih.gov/pubmed/26816540
http://dx.doi.org/10.1111/1759-7714.12275

Ejemplares similares